Holen Sie sich die Stockscreener-App
963.33
3.07%
28.73
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly (LLY) Valuation Check As GLP 1 Growth And Foundayo Approval Lift Guidance - simplywall.st
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling' - Yahoo Finance
Interchange Capital Partners LLC Has $4.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Narwhal Capital Management Sells 2,288 Shares of Eli Lilly and Company $LLY - MarketBeat
Keybank National Association OH Sells 4,443 Shares of Eli Lilly and Company $LLY - MarketBeat
Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance UK
ruist Reaffirms Buy on Eli Lilly (LLY) After Trial Success - Insider Monkey
Eli Lilly & Co Soars on Obesity-Drug Power Play - TipRanks
Eli Lilly and Company (NYSE:LLY) Given New $1,133.00 Price Target at Bank of America - MarketBeat
Vest Financial LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Position Increased by Wealthfront Advisers LLC - MarketBeat
Citi Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Comerica Bank Sells 9,402 Shares of Eli Lilly and Company $LLY - MarketBeat
Why Eli Lilly (LLY) Is Up 9.0% After Q1 Beat And Foundayo GLP‑1 LaunchAnd What's Next - simplywall.st
Cadence Bank Sells 1,042 Shares of Eli Lilly and Company $LLY - MarketBeat
Arlington Trust Co LLC Sells 2,113 Shares of Eli Lilly and Company $LLY - MarketBeat
Novo rebrands diabetes pill as Ozempic to tap blockbuster name - ET Manufacturing
Eli Lilly and Company (NYSE:LLY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Unloaded Rep. Lizzie Fletcher - MarketBeat
Eli Lilly Surge Sparks Buzz Amid S&P 500 Index Momentum - Kalkine Media
Lilly Announces Partnership To Develop AI-designed Recombinases For Genetic Medicine - InkFreeNews.com
Eli Lilly (LLY) Faces Slow Start for Foundayo in Weight Loss Mar - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 3.3% on Earnings Beat - MarketBeat
LLY Maintains Overweight by Cantor Fitzgerald -- Price Target Ra - GuruFocus
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - MarketBeat
Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - Investing.com
BofA cuts Eli Lilly stock price target on valuation concerns - Investing.com
Raised guidance lifts Eli Lilly stock to fresh highs in strong session - Traders Union
Why is Eli Lilly stock surging today? - Investing.com
Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s. - Barchart
Eli Lilly and Co Stock (LLY) Moved Up by 4.44% on May 1: Facts Behind the Movement - TradingKey
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,230 - 富途牛牛
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules - Benzinga
While Mass. biotech layoffs surge, this pharma company is on a $20B buying spree - MassLive
Eli Lilly and Company (NYSE:LLY) Q1 2026 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald raises Eli Lilly stock price target on guidance By Investing.com - Investing.com Canada
Lilly's obesity pill hits nearly 6,000 prescriptions in third week after launch - Reuters
Lilly Boosts Sales View to $85 Billion on Obesity-Drug Surge - Advisor Perspectives
Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best - TradingView
Lilly’s new weight loss pill sees rising demand - Latest news from Azerbaijan
Goldman Sachs Adjusts PT on Eli Lilly and Co. to $1,283 From $1,260, Maintains Buy Rating - Moomoo
Leerink Partners Adjusts PT on Eli Lilly and Co. to $1,119 From $1,058, Maintains Outperform Rating - marketscreener.com
Why Eli Lilly and Company (LLY) is One of the Best Drug Stocks to Buy According to Analysts - Insider Monkey
$Eli Lilly and Co (LLY.US)$ , vertical put spread option bought before earnings result. - Moomoo
Eli Lilly (LLY) Net Margin At 31.7% Tests Justification For 40.5x P/E Narrative - simplywall.st
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Stil - Benzinga
Truist Securities: Eli Lilly's Incretin Portfolio Bolsters Multi-year Growth Potential; Estimates Updated - 富途牛牛
BMO Adjusts Model for Eli Lilly After 'Standout' Q1 - Moomoo
RBC Ups Estimates for Eli Lilly Post-Q1 Results; Outperform Rating Kept - 富途牛牛
With Earnings Booming, Can Lilly Hold Its Pharma Crown? - Moomoo
Eli Lilly Sales Surge 56% as Booming GLP-1 Demand Eclipses Lower Prices - The Daily Upside
US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs - Reuters
Eli Lilly Q1 Revenue Hits $19.8B as GLP-1 Drugs Fuel Growth - Fitt Insider
GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy? - Barchart
Eli Lilly Earnings: Mounjaro/Zepbound's Massive Volume Growth More Than Counters Price Pressure - Morningstar
Eli Lilly and Co Options Spot-On: On April 30th, 89,364 Contracts Were Traded, With 341.58K Open Interest - Moomoo
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com - 富途牛牛
Eli Lilly's Cardiometabolic Dominance Is Driving Stellar Growth and Supports a Wide Moat - Morningstar
Lilly’s Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays - Investing.com
Eli Lilly (LLY) Q1 2026 Earnings Call Transcript - Fortune
Friday Five — Pfizer's LOE reprieve, Lilly's outsized earnings, Chiesi snaps up KalVista, and more… - FirstWord Pharma
More than 20k people on oral weight loss pill as Lilly ramps up access - IndyStar
Market movers: Qualcomm, Hertz, Eli Lilly, Royal Caribbean, 374Water… - Proactive financial news
Eli Lilly’s proven $19.8B quarter and what’s next - Rolling Out
Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start - Sherwood News
Why Eli Lilly stock just popped - MSN
Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth - WSJ
High-flying Lilly delivers Q1 show of strength - The Pharma Letter
Eli Lilly (LLY) Q1 2026 Earnings Transcript - The Motley Fool
1.16%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):